Hugo Fabre

1. 2023 – now

   Head of Medical Affairs, EMEA

   Terumo Blood and Cell Technologies · Brussels

   Regional Medical Affairs across therapeutic apheresis, cell collection, cell and gene therapy and transfusion.

2. 2021 – 2022

   Medical Science Liaison

   Terumo Blood and Cell Technologies

   Cell and gene therapies, cell collection and extracorporeal photopheresis.

3. 2020 – 2021

   Head of Market Development

   Firalis · precision diagnostics · Huningue

   Brought COVID-19 diagnostic products to European markets during the pandemic, and led the bid that won a US$1M grant from the Alzheimer's Drug Discovery Foundation and Bill Gates Ventures.

4. 2015 – 2018

   Lab head

   Department of Biomedical Engineering, University of Basel

   Built a lab inside the newly founded department, working on bone and soft-tissue engineering for cleft palate surgery with infants' own cord blood stem cells. Set up the partnership with the university hospital's cord blood bank and the ethics submissions behind it.

5. 2012 – 2015

   Doctoral fellow

   CTI-Biotech and LBTI (CNRS, Université Lyon 1) · Lyon

   Built an in-house flow cytometry core with BD and developed polychromatic panels to characterise and sort stem cells from adult and perinatal tissues.

6. 2007 – 2015

   PhD in tissue engineering, with honours (2015)

   MSc (2012) and BSc (2010) in cell biology and genetics · Université Claude Bernard Lyon 1

   Thesis: a flow cytometry screening method to characterise human mesenchymal stem cells from different sources and predict their potential for cartilage reconstruction.

A portfolio in progress. Published work links out. The rest is described at the level I can share: what the work was for and what part I played, not the figures.

1. 2026

   Reporting standards for cell collections

   EvidenceCo-author

   A systematic review of how mononuclear cell apheresis collections are reported, and expert recommendations for doing it consistently, written with a European group of transplant and apheresis physicians.

   Paper

2. 2026

   Leukoreduction, region by region

   EvidenceSenior author

   A systematic review of where blood component leukoreduction is implemented, what guidelines require and what it costs, across regions.

   Paper

3. 2025

   Collection efficiency, measured honestly

   EvidenceCo-author

   An analysis of how processed volume changes traditional and crude collection efficiency in stem cell collections, and what that means for comparing centres.

   Paper

4. 2025

   A survey of collection practice

   EvidenceCo-author

   A cross-sectional study of cell collection and apheresis practices in collection and transplant centres.

   Paper

5. Ongoing

   Evidence training for field teams

   EducationProgramme owner

   A recurring training series that teaches commercial and clinical colleagues to read a paper, weigh a claim and say plainly what the evidence does not show.

6. Ongoing

   Expert engagement across EMEA

   Expert engagementLead

   Mapping and engaging clinicians in transplant, apheresis and transfusion medicine across Europe, the Middle East and Africa; advisory boards in sickle cell disease and therapeutic apheresis.

7. Ongoing

   Evidence for access decisions

   AccessContributor

   Clinical and economic evidence packages that support reimbursement and health technology assessment conversations about apheresis procedures.

8. Ongoing

   A personal AI stack for medical affairs

   AutomationBuilder

   Agents that sweep my inbox and calendar, rerun literature searches, verify citations and build documents from templates, under rules I wrote and keep.

   How it works

9. 2015 – 2018

   Cord blood stem cells for cleft palate surgery

   ScienceLab head

   A tissue engineering lab set up inside the University of Basel's new biomedical engineering department: cord blood banking with the university hospital, the ethics approvals behind it, and a proof of concept of bone-forming differentiation on allogeneic bone.

10. 2012 – 2015

    A flow cytometry method for stem cell quality

    SciencePhD

    A screening method to characterise human mesenchymal stem cells from several tissues and predict their potential for cartilage repair, and an in-house cytometry core built with the instrument maker.

    Paper

11. 2020 – 2021

    Diagnostics in a pandemic

    DiagnosticsHead of Market Development

    COVID-19 diagnostic products brought to European markets, and the winning bid for a US$1M Alzheimer's Drug Discovery Foundation and Bill Gates Ventures grant.

Nothing in that area yet.

Inbox and calendar

A daily sweep of mail, calendar and chat keeps a register of open commitments, writes it into one weekly calendar slot, and drafts the replies I then edit and send.

Literature

Published searches rerun on a schedule, deduplicated and screened against frozen criteria, with a log that would survive a reviewer. Every DOI and PMID is checked against its source before a reference enters a document.

Evidence assets

One master file of the clinical evidence I work with, keyed by DOI, feeding one-pagers, training material, a searchable browser and a monthly internal newsletter.

Documents

Word and PowerPoint built from templates and delivered with tracked changes, comments and a verbatim diff, so a reviewer sees exactly what moved.

Meetings

Recordings transcribed on my own hardware; congress reports assembled from hundreds of slide photographs.

Intelligence

Competitive, regulatory and policy watch condensed into briefs; market models that show their arithmetic; a prototype dashboard that turns newsletter traffic into structured signals.

Memory

A few hundred plain-text notes with dated status snapshots, and a standing rule that the agent re-reads the live source before calling anything current.

• Read the whole source. A search locates; it never concludes.
• Nothing is cited from an abstract.
• Every number is traced to where it came from, or it is left out.
• A correction replaces the wrong text. It is never appended underneath.
• Nothing leaves without a person reading it.

1. Question and protocol

   The research questions, the eligibility criteria, the extraction plan and the quality tools are written down first and deposited with a time stamp before the first search runs. Anything that changes later is logged as an amendment, with the reason and the exact wording before and after.

2. Search

   A medical librarian turns each question into a strategy for each database, plus citation chasing and a hand-search of the specialist journals. One execution log holds every line with its date, databases and raw count. Strings are frozen once run; if screening is noisy, the fix is in the screening, never in the string.

3. Deduplication

   Three passes, each logged: exact title and year; exact title with the year off by one; then a fuzzy pass that only flags a pair when a second signal agrees, such as the same first author, journal, or year and page. Flagged pairs go to a person, and those decisions are carried forward when the corpus is rebuilt.

4. Screening

   Title and abstract against the frozen criteria. A language model reads each record and proposes include, exclude or uncertain with a reason code; I make the call. The model is declared in the protocol as a tool, calibrated on a sample before the main pass, and the protocol commits a sample of exclusions to a second reviewer.

5. Full text and extraction

   Every included paper is read in full, never from the abstract, into a fixed extraction table with a definitions sheet, and mapped to the question it answers. Quality is assessed with the tool that fits the design.

6. Synthesis and reporting

   The synthesis is written question by question. The PRISMA flow is compiled from the logs, not from memory, and every DOI and PMID is verified against its source before the reference list is final.

7. Living surveillance

   After publication the search is rerun on a schedule with the string unchanged, so the completeness claim stays defensible and new evidence is caught rather than discovered by a reviewer.

The early papers come from the bench, on stem cells and tissue engineering. The recent ones come from industry, written with transfusion, apheresis and cell therapy teams.

1. 2026

   Standardized reporting of mononuclear cell apheresis collections: a systematic review and expert recommendations

   Bonig H, Chabannon C, Charry P, Cid J, Fabre H, Fernandez-Sojo J, Henschler R, Blázquez PJ, Koh MB, le Poole K, Lozano M, Swaneveld F, Worel N

   Current Research in Translational Medicine · 74(4):103611Systematic reviewDOI PubMed

2. 2026

   Regional implementation, guideline landscape, and economic impact of blood component leukoreduction: a systematic literature review

   Comasòlivas N, Cid J, Fabre H

   Blood Transfusion · published online September 2026Systematic reviewLast authorDOI PubMed

3. 2025

   From Traditional to Crude Collection Efficiency: A Comprehensive Analysis of the Impact of Processed Volume

   Fernandez-Sojo J, Linares M, Gomez-Vives D, Pons V, Ayats J, Rierola M, Albert M, Alonso S, Garcia-Buendia A, Castillo-Flores N, Codinach M, Torrents S, Aran G, Fabre H, Jarabo P, Lewandowski S, Querol S, Parra R

   Journal of Clinical Apheresis · 40(6):e70081ArticleDOI PubMed

4. 2025

   Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers

   Azar N, Chao NJ, Cliquennois M, Geske M, Henzan T, Kent T, Poullin P, Shore TB, Cawson M, Fabre H, Waltl F

   Transfusion and Apheresis Science · 64(6):104251ArticleDOI PubMed

5. 2025

   Large-Scale Expansion of Suspension Cells in an Automated Hollow-Fiber Perfusion Bioreactor

   Bräuchle E, Knaub M, Weigand L, Ehrend E, Manns P, Kremer A, Fabre H, Bonig H

   Bioengineering · 12(6):644ArticleDOI PubMed Free full text Correction

6. 2021

   Flow Cytometry Analysis of Type IIB Procollagen as Quality Control of Chondrogenic Commitment of MSCs

   Perrier-Groult E, Aubert-Foucher E, Pasdeloup M, Lafont J, Fabre H, Mallein-Gerin F

   Stem Cells and Regenerative Medicine (IOS Press) · Biomedical and Health Research seriesBook chapterDOI

7. 2019

   Characterization of Different Sources of Human MSCs Expanded in Serum-Free Conditions with Quantification of Chondrogenic Induction in 3D

   Fabre H, Ducret M, Degoul O, Rodriguez J, Perrier-Groult E, Aubert-Foucher E, Pasdeloup M, Auxenfans C, McGuckin C, Forraz N, Mallein-Gerin F

   Stem Cells International · 2019:2186728ArticleFirst authorDOI PubMed Free full text

8. 2019

   Phenotypic Identification of Dental Pulp Mesenchymal Stem/Stromal Cells Subpopulations with Multiparametric Flow Cytometry

   Ducret M, Farges JC, Pasdeloup M, Perrier-Groult E, Mueller A, Mallein-Gerin F, Fabre H

   Methods in Molecular Biology · 1922:77–90ProtocolLast authorDOI PubMed

9. 2017

   Current challenges in human tooth revitalization

   Ducret M, Fabre H, Celle A, Mallein-Gerin F, Perrier-Groult E, Alliot-Licht B, Farges JC

   Bio-Medical Materials and Engineering · 28(s1):S159–S168ReviewCo-first authorDOI PubMed

10. 2017

    Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study

    Rodriguez J, Pratta AS, Abbassi N, Fabre H, Rodriguez F, Debard C, Adobati J, Boucher F, Mallein-Gerin F, Auxenfans C, Damour O, Mojallal A

    Stem Cells International · 2017:9289213ArticleDOI PubMed Free full text

11. 2016

    Immunophenotyping Reveals the Diversity of Human Dental Pulp Mesenchymal Stromal Cells In vivo and Their Evolution upon In vitro Amplification

    Ducret M, Fabre H, Degoul O, Atzeni G, McGuckin C, Forraz N, Mallein-Gerin F, Perrier-Groult E, Alliot-Licht B, Farges JC

    Frontiers in Physiology · 7:512ArticleCo-first authorDOI PubMed Free full text

12. 2016

    A standardized procedure to obtain mesenchymal stem/stromal cells from minimally manipulated dental pulp and Wharton's jelly samples

    Ducret M, Fabre H, Degoul O, Atzeni G, McGuckin C, Forraz N, Mallein-Gerin F, Perrier-Groult E, Farges JC

    Bulletin du Groupement International pour la Recherche Scientifique en Stomatologie et Odontologie · 53(1):e37ArticlePubMed

13. 2015

    Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations

    Ducret M, Fabre H, Degoul O, Atzeni G, McGuckin C, Forraz N, Alliot-Licht B, Mallein-Gerin F, Perrier-Groult E, Farges JC

    Frontiers in Physiology · 6:213ArticleCo-first authorDOI PubMed Free full text

14. 2015

    Production of Human Dental Pulp Cells with a Medicinal Manufacturing Approach

    Ducret M, Fabre H, Farges JC, Degoul O, Atzeni G, McGuckin C, Forraz N, Mallein-Gerin F, Perrier-Groult E

    Journal of Endodontics · 41(9):1492–1499ArticleCo-first authorDOI PubMed

15. 2014

    Cartilage tissue engineering: molecular control of chondrocyte differentiation for proper cartilage matrix reconstruction

    Demoor M, Ollitrault D, Gomez-Leduc T, Bouyoucef M, Hervieu M, Fabre H, Lafont J, Denoix JM, Audigié F, Mallein-Gerin F, Legendre F, Galera P

    Biochimica et Biophysica Acta · 1840(8):2414–2440ReviewDOI PubMed

Nothing matches that filter.

In the air

Private pilot licence

On foot

Marathons

On two wheels

Motorbikes

In my hands

Classical guitar

On the wrist

Mechanical watches

In the kitchen

Fine cooking

In my ears

Romantic-era music and minimal techno

On the shelf

Philosophy, politics, technology

Email is the best way to reach me. I work in English and French.

• LinkedIn
• ORCID 0000-0002-3214-6878